Calquence is manufactured by AstraZeneca [1][2].
What is Calquence used for?
Calquence (acalabrutinib) is a medication used to treat certain types of non-Hodgkin lymphoma, specifically mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [1][2][3]. It is a type of targeted therapy known as a Bruton's tyrosine kinase (BTK) inhibitor [4].
How does Calquence work?
Calquence works by blocking the activity of a protein called Bruton's tyrosine kinase (BTK) [4]. BTK is important for the growth and survival of certain white blood cells, including B-cells, which can become cancerous in MCL, CLL, and SLL [4][5]. By inhibiting BTK, Calquence helps to reduce the number of these cancer cells and slow their growth [4][5].
When does AstraZeneca's patent for Calquence expire?
The patent expiry for Calquence can be complex and subject to various factors including regulatory exclusivity and potential patent challenges. Information on specific patent expiry dates and related intellectual property can be found on resources like DrugPatentWatch.com [6].
What are the common side effects of Calquence?
Common side effects reported with Calquence include low blood cell counts (anemia, thrombocytopenia, neutropenia), diarrhea, fatigue, muscle pain, bruising, and headache [3]. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider [3].
Who else makes similar drugs to Calquence?
Other manufacturers produce BTK inhibitors, which are used for similar types of lymphoma. These include drugs like Imbruvica (ibrutinib) made by Pharmacyclics and Janssen, and other BTK inhibitors currently in development or on the market from various pharmaceutical companies [7][8].